CDC CLASSIFICATION SYSTEM FOR HIV INFECTION

The CDC categorization of HIV/AIDS is based on the lowest documented CD4 cell count and on previously diagnosed HIV-related conditions (see Table 1). For example, if a patient had a condition that once met the criteria for category B but now is asymptomatic, the patient would remain in category B. Additionally, categorization is based on specific conditions, as indicated below. Patients in categories A3, B3, and C1-C3 are considered to have AIDS.

Table 1. CDC Classification System for HIV-Infected Adults and Adolescents
CD4 Cell Categories Clinical Categories
Abbreviations: PGL = persistent generalized lymphadenopathy

 

A
Asymptomatic, Acute HIV, or PGL
B*
Symptomatic Conditions, not A or C
C#
AIDS-Indicator Conditions
(1) ≥500 cells/µL A1 B1 C1
(2) 200-499 cells/µL A2 B2 C2
(3) <200 cells/µL A3 B3 C3

* Category B Symptomatic Conditions Category B symptomatic conditions are defined as symptomatic conditions occurring in an HIV-infected adolescent or adult that meets at least one of the following criteria:

They are attributed to HIV infection or indicate a defect in cell-mediated immunity.

They are considered to have a clinical course or management that is complicated by HIV infection. Examples include, but are not limited to, the following:
  • Bacillary angiomatosis
  • Oropharyngeal candidiasis (thrush)
  • Vulvovaginal candidiasis, persistent or resistant
  • Pelvic inflammatory disease (PID)
  • Cervical dysplasia (moderate or severe)/cervical carcinoma in situ
  • Hairy leukoplakia, oral
  • Herpes zoster (shingles), involving two or more episodes or at least one dermatome
  • Idiopathic thrombocytopenic purpura
  • Constitutional symptoms, such as fever (>38.5ºC) or diarrhea lasting >1 month
  • Peripheral neuropathy
# Category C AIDS-Indicator Conditions
  • Bacterial pneumonia, recurrent (two or more episodes in 12 months)
  • Candidiasis of the bronchi, trachea, or lungs
  • Candidiasis, esophageal
  • Cervical carcinoma, invasive, confirmed by biopsy
  • Coccidioidomycosis, disseminated or extrapulmonary
  • Cryptococcosis, extrapulmonary
  • Cryptosporidiosis, chronic intestinal (>1 month in duration)
  • Cytomegalovirus disease (other than liver, spleen, or nodes)
  • Encephalopathy, HIV-related
  • Herpes simplex: chronic ulcers (>1 month in duration), or bronchitis, pneumonitis, or esophagitis
  • Histoplasmosis, disseminated or extrapulmonary
  • Isosporiasis, chronic intestinal (>1-month duration)
  • Kaposi sarcoma
  • Lymphoma, Burkitt, immunoblastic, or primary central nervous system
  • Mycobacterium avium complex (MAC) or Mycobacterium kansasii, disseminated or extrapulmonary
  • Mycobacterium tuberculosis, pulmonary or extrapulmonary
  • Mycobacterium, other species or unidentified species, disseminated or extrapulmonary
  • Pneumocystis jiroveci (formerly carinii) pneumonia (PCP)
  • Progressive multifocal leukoencephalopathy (PML)
  • Salmonella septicemia, recurrent (nontyphoid)
  • Toxoplasmosis of brain
  • Wasting syndrome caused by HIV (involuntary weight loss >10% of baseline body weight) associated with either chronic diarrhea (two or more loose stools per day for ≥1 month) or chronic weakness and documented fever for ≥1 month
HIV AIDS treatment is not complicated, knowing what drugs you are taking, how they work against HIV, and why it is so important to take them as prescribed (on time, with or without food, etc.) can really help in the fight against HIV. HIV AIDS treatment is safer, if your treatment consists of toxic free, side-effect free medications. HIV AIDS treatment becomes more comfortable, if your treatment doesn’t ask for switching on to new drug combination because of drug resistance. HIV AIDS treatment is not complicated, knowing what drugs you are taking, how they work against HIV, and why it is so important to take them as prescribed (on time, with or without food, etc.) can really help in the fight against HIV. HIV AIDS treatment is safer, if your treatment consists of toxic free, side-effect free medications. HIV AIDS treatment becomes more comfortable, if your treatment doesn’t ask for switching on to new drug combination because of drug resistance.